SCHEMBL793625

SCHEMBL793625

OC1CNc2ccccc21

nearest known ligand 0.48

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CHRNB4 P30926 1/20 0.37
CHRNA3 P32297 1/20 0.37
PARP3 Q9Y6F1 1/20 0.35
PAX8 Q06710 1/20 0.35
MEN1 O00255 1/20 0.34
GAA P10253 1/20 0.34
KMT2A Q03164 1/20 0.34
ALDH1A1 P00352 1/20 0.34
KCNH2 Q12809 1/20 0.34
CCKBR P32239 2/20 0.33
MTNR1A P48039 1/20 0.33
MTNR1B P49286 1/20 0.33
MAOA P21397 1/20 0.32
MAOB P27338 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8703745 1.00 CHRNB4 (0.37) CHRNB4CHRNA3PARP3PAX8MEN1
SCHEMBL29636531 1.00 CHRNB4 (0.37) CHRNB4CHRNA3PARP3PAX8MEN1
SCHEMBL30290030 0.78 F12 (0.36) MEN1GAAKMT2AALDH1A1
SCHEMBL2172550 0.78 F12 (0.36) MEN1GAAKMT2AALDH1A1
SCHEMBL4207481 0.78 PARP3 (0.40) CHRNB4CHRNA3PARP3PAX8MEN1
SCHEMBL224810 0.78 F12 (0.36) MEN1GAAKMT2AALDH1A1
SCHEMBL2172225 0.78 F12 (0.36) MEN1GAAKMT2AALDH1A1
Hydrochloric Acid SCHEMBL27979283 0.77 ALDH1A1 (0.37) MEN1GAAKMT2AALDH1A1
SCHEMBL30417082 0.76 CHRNB4 (0.39) CHRNB4CHRNA3PARP3PAX8MEN1
Ethane SCHEMBL11061598 0.75 BCHE (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111825686-A Oxazepino [3,2-b ] indole compound and synthetic method thereof 贵州医科大学 2020-10-27 CN claimed
US-20170281805-A1 NOVEL ANTHRANILIC ACID DERIVATIVES MAHESHWARI DIVYA (IN) 2017-10-05 US claimed
EP-3200779-A2 NOVEL ANTHRANILIC ACID DERIVATIVES Maheshwari, Divya (IN) 2017-08-09 EP claimed
EP-2621902-B1 3-AZABICYCLO[3.1.0]HEXANE COMPOUNDS USEFUL FOR THE TREATMENT OF CNS DISORDERS PANACEA BIOTEC LTD (IN) 2017-04-12 EP claimed
CN-104744476-B IMIDAZOPYRAZINE Syk INHIBITORS 吉利德康涅狄格公司 2017-04-12 CN claimed
WO-2016051306-A2 NOVEL ANTHRANILIC ACID DERIVATIVES MAHESHWARI DIVYA (IN) 2016-04-07 WO claimed
US-20150218155-A1 BICYCLIC HETEROAROMATIC COMPOUNDS MERCK PATENT GMBH (DE) 2015-08-06 US claimed
EP-2748164-A1 BICYCLIC HETEROAROMATIC COMPOUNDS Merck Patent GmbH (DE) 2014-07-02 EP claimed
US-8455479-B2 Heterocyclic compounds PANACEA BIOTEC LIMITED (IN) 2013-06-04 US claimed
WO-2013026516-A1 BICYCLIC HETEROAROMATIC COMPOUNDS MERCK PATENT GMBH (DE) 2013-02-28 WO claimed
US-20130029944-A1 INHIBITORS OF PROTEIN KINASES PORTOLA PHARMACEUTICALS, INC. (US) 2013-01-31 US claimed
EP-2271631-A2 INHIBITORS OF PROTEIN KINASES Portola Pharmaceuticals, Inc. (US) 2011-01-12 EP claimed
WO-2009131687-A2 INHIBITORS OF PROTEIN KINASES PORTOLA PHARMACEUTICALS, INC. (US) 2009-10-29 WO claimed
EP-1150565-A1 THIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF LION bioscience AG (DE) 2001-11-07 EP claimed
WO-2000045635-A1 THIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF LION BIOSCIENCE AG (DE) 2000-08-10 WO claimed
US-20250090540-A1 PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF RELAY THERAPEUTICS, INC. 2025-03-20 US disclosed
EP-4399196-A1 PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF Relay Therapeutics, Inc. (US) 2024-07-17 EP disclosed
EP-1489540-A1 INFORMATION PROVIDING SYSTEM AND PAPER-SHAPED DISPLAY MEDIUM DAI NIPPON PRINTING CO., LTD. (JP) 2004-12-22 EP disclosed
EP-1150565-A1 THIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF LION bioscience AG (DE) 2001-11-07 EP disclosed
WO-2000045635-A1 THIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF LION BIOSCIENCE AG (DE) 2000-08-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170281805-A1 NOVEL ANTHRANILIC ACID DERIVATIVES SLC47A1, ABCC1, ABCB1 CHRNB4 3747/4885CHRNA3 4161/4885PARP3 2102/4885
US-20150218155-A1 BICYCLIC HETEROAROMATIC COMPOUNDS CDK1, CDK2, CDK4 CHRNB4 2086/4885CHRNA3 1735/4885PARP3 555/4885
US-20130029944-A1 INHIBITORS OF PROTEIN KINASES SYK, BTK, JAK2 CHRNB4 4884/4885CHRNA3 4876/4885PARP3 1247/4885
US-20250090540-A1 PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF PIK3CA, PIK3CB, PIK3CD CHRNB4 3970/4885CHRNA3 3914/4885PARP3 946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.